These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 26949069)

  • 1. [The role of atherogenic dyslipidaemia in clinical practice guidelines].
    Pedro-Botet J; Mantilla-Morató T; Díaz-Rodríguez Á; Brea-Hernando Á; González-Santos P; Hernández-Mijares A; Pintó X; Millán Núñez-Cortés J
    Clin Investig Arterioscler; 2016; 28(2):65-70. PubMed ID: 26949069
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Triglycerides, HDL cholesterol and atherogenic dyslipidaemia in the 2019 European guidelines for the management of dyslipidaemias.
    Pedro-Botet J; Ascaso JF; Blasco M; Brea Á; Díaz Á; Hernández-Mijares A; Pintó X; Millán J;
    Clin Investig Arterioscler; 2020; 32(5):209-218. PubMed ID: 32037300
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Atherogenic dyslipidemia: a multidisciplinary consensus panel].
    Foro Dislipidemia Aterogénica
    Clin Investig Arterioscler; 2013; 25(2):83-91. PubMed ID: 23747118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Practical recommendations for the management of cardiovascular risk associated with atherogenic dyslipidemia, with special attention to residual risk. Spanish adaptation of a European Consensus of Experts.
    Grupo de trabajo de Dislipemia Aterogénica de la Sociedad Española de Arteriosclerosis y Grupo Europeo de Expertos
    Clin Investig Arterioscler; 2017; 29(4):168-177. PubMed ID: 28433209
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Therapeutic targets in the treatment of dyslipidemia: HDL and non-HDL cholesterol].
    Brea Hernando ÁJ
    Clin Investig Arterioscler; 2014 Jul; 26 Suppl 1():3-6. PubMed ID: 25043539
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Diabetic dyslipidaemia and the atherosclerosis].
    Márk L; Dani G
    Orv Hetil; 2016 May; 157(19):746-52. PubMed ID: 27133274
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Residual cardiovascular risk of lipid origin. Components and pathophysiological aspects.
    Hernández-Mijares A; Ascaso JF; Blasco M; Brea Á; Díaz Á; Mantilla T; Pedro-Botet J; Pintó X; Millán J;
    Clin Investig Arterioscler; 2019; 31(2):75-88. PubMed ID: 30262442
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Dyslipidaemia and vascular risk. A new evidence based review].
    Pallarés-Carratalá V; Pascual-Fuster V; Godoy-Rocatí D
    Semergen; 2015; 41(8):435-45. PubMed ID: 25559484
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The real measurement of non-HDL-cholesterol: Atherogenic cholesterol].
    Millán J; Hernández-Mijares A; Ascaso JF; Blasco M; Brea A; Díaz Á; González-Santos P; Mantilla T; Pedro-Botet J; Pintó X;
    Clin Investig Arterioscler; 2016; 28(6):265-270. PubMed ID: 27633523
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How to assess and manage cardiovascular risk associated with lipid alterations beyond LDL.
    Averna M; Stroes E;
    Atheroscler Suppl; 2017 Apr; 26():16-24. PubMed ID: 28434480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence and treatment of atherogenic dyslipidemia in the primary prevention of cardiovascular disease in Europe: EURIKA, a cross-sectional observational study.
    Halcox JP; Banegas JR; Roy C; Dallongeville J; De Backer G; Guallar E; Perk J; Hajage D; Henriksson KM; Borghi C
    BMC Cardiovasc Disord; 2017 Jun; 17(1):160. PubMed ID: 28623902
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The application of atherogenic dyslipidaemia consensus recommendations in the primary care setting. DAT-AP study.
    Rodríguez AD; Cumplido AS; Nuñez-Cortés JM; Rodríguez de Miguel M; Orera-Peña ML
    Clin Investig Arterioscler; 2017; 29(4):178-184. PubMed ID: 28648670
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patient.
    Fruchart JC; Sacks FM; Hermans MP; Assmann G; Brown WV; Ceska R; Chapman MJ; Dodson PM; Fioretto P; Ginsberg HN; Kadowaki T; Lablanche JM; Marx N; Plutzky J; Reiner Z; Rosenson RS; Staels B; Stock JK; Sy R; Wanner C; Zambon A; Zimmet P;
    Diab Vasc Dis Res; 2008 Nov; 5(4):319-35. PubMed ID: 18958843
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 'Trig-onometry': non-high-density lipoprotein cholesterol as a therapeutic target in dyslipidaemia.
    Jacobson TA
    Int J Clin Pract; 2011 Jan; 65(1):82-101. PubMed ID: 21105969
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A review of the evidence on reducing macrovascular risk in patients with atherogenic dyslipidaemia: A report from an expert consensus meeting on the role of fenofibrate-statin combination therapy.
    Aguiar C; Alegria E; Bonadonna RC; Catapano AL; Cosentino F; Elisaf M; Farnier M; Ferrières J; Filardi PP; Hancu N; Kayikcioglu M; Mello E Silva A; Millan J; Reiner Ž; Tokgozoglu L; Valensi P; Viigimaa M; Vrablik M; Zambon A; Zamorano JL; Ferrari R
    Atheroscler Suppl; 2015 Sep; 19():1-12. PubMed ID: 26315511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [New European guidelines for the management of dyslipidaemia in cardiovascular prevention].
    Descamps OS; De Backer G; Annemans L; Muls E; Scheen AJ; ;
    Rev Med Liege; 2012 Mar; 67(3):118-27. PubMed ID: 22611827
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An evidence-based analysis of the National Lipid Association recommendations concerning non-HDL-C and apoB.
    Sniderman AD; Toth PP; Thanassoulis G; Furberg CD
    J Clin Lipidol; 2016; 10(5):1248-58. PubMed ID: 27678443
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of expert consensus to improve atherogenic dyslipidemia management.
    Millán Núñez-Cortés J; Pedro-Botet J; Brea-Hernando Á; Díaz-Rodríguez Á; González-Santos P; Hernández-Mijares A; Mantilla-Morató T; Pintó-Sala X; Simó R
    Rev Esp Cardiol (Engl Ed); 2014 Jan; 67(1):36-44. PubMed ID: 24774262
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The metabolic and pharmacologic bases for treating atherogenic dyslipidaemia.
    Chan DC; Barrett PH; Watts GF
    Best Pract Res Clin Endocrinol Metab; 2014 Jun; 28(3):369-85. PubMed ID: 24840265
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.